A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

NCT05698303 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)

Sponsor

Nanjing IASO Biotechnology Co., Ltd.